SureTrader Advertisement PRTC
Home > Boards > US OTC > Cannabis >

GrowBlox Sciences, Inc. (GBLX)

Add GBLX Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 5/4/2016 11:42:48 AM - Followers: 110 - Board type: Free - Posts Today: 0

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space.

Investment Highlights

  • Novel Approach to Cannabis-based Medicine
    Industry-Leading, Turnkey Business Solution
    Accelerated Drug Development Program
    Patent Protected Processes & Formulations
    Powerful Intellectual Property Strategy
    Unlocking the Path to Drug Discovery
    Highly Unified, Qualified Management Team


Technology Suite

The GrowBLOX technology suite provides unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP (current good manufacturing practice) guidelines.


GBLX’s innovative TissueBLOX system is designed to ensure genetic uniformity of GB Sciences’ proprietary strains. The tissue culture incubator is programmed to regulate lighting, temperature, and humidity to facilitate cell multiplication and the formation of embryos and shoots from the sterile explants. After roots form, the plantlets are transferred to another module where the roots are placed into aeroponic media blocks and the plant adapts for life in a GrowBLOX chamber.



After transfer from the tissue culture box, the plantlets are grown in a completely controlled environment. Temperature, humidity, lighting, CO2 and nutrition are programmed to meet the specific needs of the cannabis strain that is grown throughout the grow cycle. The plants are protected from any outside pollutants or germs. The only time the chambers are opened is for trimming.

Years of development under the direction of GBLX’s Chief Engineer Wayne Love were necessary to create the GrowBLOX. Using the most advanced and reliable components on the market, every GrowBLOX can be remotely monitored and programmed from mobile devices or from the company’s central grow facility.

Years of development under the direction of GBLX’s Chief Engineer Wayne Love were necessary to create the GrowBLOX. Using the most advanced and reliable components on the market, every GrowBLOX can be remotely monitored and programmed from mobile devices or from the company’s central grow facility.



The CureBLOX drying system matches plant strains to an optimal temperature, pressure, and humidity algorithm to ensure perfectly cured, pathogen-free medicine. CureBLOX cabinets adjust the ambient humidity, temperature, and air pressure inside the chamber to regulate the movement of moisture inside the plant material. This preserves the medicinal cannabinoids and terpenes while removing any potential molds or contaminants. This curing process usually takes between eight and 12 days


GB Sciences – From Plant to Medicine

Product Claims * Medical Research * Lab Testing * Clinical Trials * FDA Compliance * Data Analytics

GB Sciences has developed its proprietary GrowBLOX technology suite to control the growth of cannabis and other plants with high medicinal value to a pharmaceutical-industry quality standard. The GrowBLOX system allows the company to create “GBLX” branded, patented and certified therapeutic mixtures of raw plant ingredients through a comprehensive GBLX Quality Management Program. GB Sciences then acts as the central hub for testing the GBLX-certified materials in a technologically data-driven biopharmaceutical innovation system that aims to create and validate novel cannabis-based therapies for patients with clinically unmet needs.

In order to treat specific disease categories with cannabis-based products, the company must correlate the profiles of active ingredients with symptom and disease-specific improvements. These active ingredients include both cannabinoids and terpenes, which have been shown to be effective in the treatment of conditions including pain management, mood, metabolism, inflammation, cancer, neural and immune disorders.

Targeted Treatment Categories

Based on an analysis of preclinical and clinical data from 1000s of peer-reviewed studies, GBLX has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven GBLX targeted therapeutic categories. The company then classified natural cannabis strains containing the ideal ratios for treating specific diseases, or symptoms within these GBLX targeted treatment categories by performing a preliminary cluster analysis of the active ingredient profiles of 30,000 cannabis strains in conjunction with a major testing lab.

  • Cancer Treatments - $114 billion (2018)
    • nausea, appetite, cancer growth

    Cardioprotection - $187 billion (2018)
    • ischemi, inflammation, circulation

    Metabolic Syndrome - $139.5 billion (2017)
    • blood sugar, appetite

    Pain Management - $29.47 billion (2018)
    • acute pain, inflammation pain, chronic pain

    Neurological Disorders - $952 billion (2018)
    • insomnia, anxiety, spasms, epileptic seizures, psychosis, depression, protect nerves

    Inflammation - $85.9 billion (2017)
    • Gastritis, psoriasis

    Compromised Immune System - $38 billion (2018)
    • Immunostimulant, nausea, wasting syndrome


5 GB Sciences Drug Discovery Advantages

The GBLX Drug Discovery Program has 5 strategic advantages that allow the company to patent protect the GBLX Accelerated Drug Development Program to finish in 3-5 years instead of the 15-20 years required in the traditional pharmaceutical development program.

  1. Certified Cannabis Extracts = Clinical Testing Materials
    Phase IV Human Trials > Medical Cannabis Dispensaries
    GBLX-PRO APP = Drug Discovery Engine
    Accelerated Regulatory Strategy > Fast Track Approvals
    GBLX Research Partners GBLX Drug Development Ecosystem

How the Accelerated Development Program Works

How do you get from phase I to phase IV human trials in less than 15 years and for less than $1 billion? Start with phase IV. Under state-regulated medical marijuana programs, GB Sciences can validate the effectiveness of its cannabis-based therapies in human phase IV clinical trials (1) that are coordinated through the GBLX-PRO smartphone app (2). The GBLX-PRO app coordinates strain profile information with symptom relief as a part of the GBLX Drug Discovery Program. The GBLX Accelerated Regulatory Strategy leverages established cannabis safety profiles as well as fast-track approvals or orphan drug designations to reduce clinical trial times and expenses (3). GBLX is also able to earn revenue from sales of the certified raw materials through dispensaries sales during the drug discovery process (4).


GB Sciences Puerto Rico, LLC

Manufacturing Supply Chain * Industrial Design * Cultivation Technology * Systems Validation * Standard Operating Procedures * Certified Raw Materials

GBLX has entered into an exclusive, worldwide commercialization agreement with GB Sciences Puerto Rico, LLC (GBS PR) to manufacture, lease, license, validate, service and finance all components of the existing and future GrowBLOX™ technology suite of cultivation and growing equipment chambers. Growblox Sciences' GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment.

GB Sciences Puerto Rico will engage in: (a) the worldwide leasing, licensing and servicing of units of the GrowBLOX technology suite, (b) cannabis propagation services and cryogenic banking of cannabis genotypes, (c) remote diagnostic and monitoring service contracts for GBLX local partners and third party growers, and (d) cultivation of medical cannabis or hemp in Puerto Rico under a comprehensive quality management program to produce cGMP-certified raw cannabis materials to be sold only to GBLX after obtaining the appropriate regulatory approvals. GBS PR will take the lead in implementing current cGMP during the cultivation and extraction of cannabis materials. The creation of cGMP-certified cannabis materials is the key for GBLX to validate efficacy claims, which drive ingredient sales across multiple manufacturing sectors including nutraceuticals, cosmeceuticals, and pharmaceuticals.

GB Sciences Puerto Rico brings safe and consistent cannabis to patients and consumers by formulating certified raw cannabis materials for clinical testing and commercialization through multiple channels.

Why Puerto Rico

Puerto Rico provides GB Sciences with a unique opportunity to validate and commercialize the GrowBLOX technology suite in order to provide certified raw materials. GB Sciences will utilize the surplus capacity on the island of Puerto Rico to rapidly advance GBLX technology.

Puerto Rico offers:

  1. Trained biopharmaceutical personnel
    World class clinical research facilities
    Land for growing industrial hemp
    Favorable tax structure to support research
    Status as an economic free zone which favors the site for future exports


GB Products – Locking in Industry Standards

Product Design * Compound Formulations * Packaging * Branding * Marketing * Distribution

GB Sciences is developing a comprehensive line of highly effective cannabis-based therapies ranging from custom medical compounds to consumer health & beauty products. The GB Sciences cultivation methodology ensures a consistent ratio of the plant’s medicinal properties for each and every harvest. This is a critical factor when creating formulations for standardized therapeutic products.

GB Sciences' Product Development Approach relies on:

  1. Creation of cGMP-certified raw cannabis materials in the GrowBLOX
    Isolation of active cannabinoid and terpenoid ingredients from the raw materials in post-processing procedures.

The key factors to transforming plants into true medicine involves consistency in dosing, quality and efficacy. In order to accomplish these goals, the company first process the whole plant and measure the individual cannabinoid and terpenoid profiles within different cannabis strains. GBLX tests these natural combinations of active ingredients for effectiveness in human phase IV trials. Then the company can isolate individual active ingredients from the cannabis plant and compound the ideal ratios based on the desired effect for specific treatments. This ensures that the appropriate combinations of active cannabis-based ingredients are consistently produced and can be properly dosed within an effective treatment plan.

GBLX Series Product Line

The GBLX line of products is the signature collection of cannabinoid therapies developed and produced by GB Sciences. Infused with certified-active ingredients derived from cannabis plants grown using the GrowBLOX system. This line of product features proprietary cannabinoid and terpenoid blends that are being extensively studied for optimal efficacy. The GBLX line will be medically dosed and prepackaged in order to give patients the same assurance of quality that they expect from all other medicines sold on the market.

GB Sciences RX – CBD Infused Skincare line

GB Sciences introduces a CBD infused anti-aging skin care product line. Developed by a world-class team of doctors and researchers, this collection of products features cellular rejuvenating and therapeutic properties derived from GBLX’s proprietary hemp strains grown in the tropics.

Distribution Strategy

The Apothecary

GB Sciences has designed a unique retail environment for cannabinoid therapy providers to deliver exceptional patient care. The Apothecary by GB Sciences combines a simple, clean and clinical design with cutting edge bio-metrics and patient verification to deliver a pleasant and safe customer experience.

The custom design elements are easily recognizable and include:

  • Security foyer
    Waiting room
    Consultation room
    Retail display
    Payment station
    Pick-up Security platform

Micro Apothecary

The Apothecary by GB Sciences introduces the Micro Apothecary self-service vending kiosk. The interactive LED monitors display essential product and patient safety information and doubles as the touch screen interface that allows you to create a new patient profile or sign in to an existing account. Once a patient is validated in the system, purchasing inventory is quick and easy.

The Micro Apothecary offers a consistent consumer experience that can now be installed in any existing retail location or traditional pharmacy permitted to sell medical cannabis products. With the strong focus to increase distribution channel exponentially without the normal cost of a traditional “brick & mortar” location, the Micro Apothecary will ensure the accessibility for patients more conveniently.

Mobile App

The Apothecary mobile app is powerful tool for building a strong patient- dispensary relationship.

The App features include:

  • Patient profile generator
    Symptom tracker
    Inventory browser
    Online order engine
    Secure payment processing
    Delivery / pickup setup


IP & Regulatory Strategy

The ability to patent protect processes and formulations is central to value creation at GB Sciences. GBLX’s intellectual property strategy takes full advantage of the design and utility of its GrowBLOX technology suite; as well as, the processes for creating certified raw cannabis materials and pharmaceutical compositions. Cannabis-based products have an advantage in regulated industries because of the current separation of state and federal guidance.

GB Sciences' product development pathway is divided based on its core operations: Cultivation, Post-Processing, and Manufacturing. Cultivation and Certified Materials are regulated by state medical marijuana laws, whereas GBLX Proprietary Blends and Manufacturing are regulated by Federal Agencies, such as the DEA, NIDA and the U.S. FDA.



Craig Ellins - CEO & Director

Craig Ellins is known as an innovative entrepreneur who has consistently and accurately identified emerging market trends and created companies with proprietary products to capitalize on these trends.

After beginning his career in the import/export industry, Ellins has gone on to create innovative companies in areas ranging from technology and media to hydroponic food production and medical cannabis patient advocacy. In recent years, Ellins has become a highly respected industry expert in the emerging medical cannabis market. As chairman of Phototron Holdings, Inc. (PHOT) in 2009, Ellins created an education program to help medical cannabis patients cultivate personal medical cannabis. Ellins then developed GrowBLOX™, the cutting-edge medical-grade hydroponic growing chambers specifically designed for the cultivation of symptom-specific medicinal cannabis strains.

These chambers are the flagship growing mechanism for GB Sciences Nevada. Ellins’s unmatched care for patients has been fueled by his long-time desire to make medical cannabis available to those who need it. His own mother, Margie, became ill several years ago and was in such tremendous pain that the doctors didn’t know how to effectively help her. After turning to medical cannabis treatments and seeing the incredible results, he knew he must continue his efforts in the burgeoning medical cannabis industry.

Through years of study, patient advocacy, and research into specific strains, Ellins has helped hundreds of patients with medical cannabis cultivation education and support. Because he has seen firsthand how patients respond positively to medical cannabis treatments, he has dedicated his life to improving the lives of others through innovation in the medical cannabis industry. Ellins is also the founder of The Newmanity Living Foundation, a nonprofit 50l(c)(3) dedicated to the cultivation and distribution of locally grown, pesticide and herbicide-free organic produce.


Catheryn Kennedy - Chief Financial Officer

Cathryn Kennedy has experience in a number of different financial roles at firms ranging from start-ups to public companies, she will be invaluable in supporting our growth as we work to bring relief to patients in communities across the country through medical marijuana.

Prior to joining GBLX, Kennedy served in a number of financial roles, including as CFO of eCommLink Inc. and as director of SEC Reporting at Pinnacle Entertainment Inc. between 2005 and 2008. She was integral in establishing corporate governance policies, managing complex transaction processing, and handling M&A in these previous roles.


Dr. Andrea Small-Howard - Chief Scientific Officer

Dr. Andrea Small-Howard leverages broad bio-pharmaceutical industry knowledge and contacts in her current dual roles as the chief science officer and member of the board of directors at GBLX.

She brings to the company a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline based on the companies’ proprietary technology suite, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All¬University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a research assistant professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As vice president of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

In 2011, Dr. Small-Howard founded International Biotechnology Solutions to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she has successfully completed projects within the areas of business development, corporate alliance building, product commercialization, corporate restructuring, and management of successful fundraising campaigns.

Currently, she also serves on the board of directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.


Lucas Marin - Director of Product Development, Founding Member

In addition to being director of product development, Lucas Marin is also a founding member of the GBLX team.

With a solid background in new product development and industrial design, Marin brings to the team a strong comprehension of managing logistics and supply chains for the bioceutical and nutraceutical markets.

Most recently, Marin has worked on developing antibacterial topical compounds and surfactants for professional sports and private medical facilities.

In addition to his experience in development of new products Marin has spent the last decade designing experiential marketing campaigns and product launches for top-tier organizations such as Medco, AOL, Spring and WIRED Magazine.



Growblox Sciences, Inc.
6450 Cameron St., Suite 110
Las Vegas, NV 89118
Phone: (817) 945-6448

QualityStocks Investor Relations
3370 N. Hayden Rd. Suite 123-591
Scottsdale, AZ 85251
Phone: (480) 374-1336


QualityStocks was a moderator of this board. Please see disclaimer on the QualityStocks website:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
GBLX News: Current Report Filing (8-k) 05/04/2016 04:54:56 PM
GBLX News: Current Report Filing (8-k) 04/14/2016 04:22:49 PM
GBLX News: Quarterly Report (10-q) 02/16/2016 02:21:25 PM
GBLX News: Current Report Filing (8-k) 02/12/2016 04:38:17 PM
GBLX News: Small Company Offering and Sale of Securities Without Registration (d) 01/13/2016 05:14:39 PM
#31   post Heisenberg 03/05/10 10:37:18 PM
#30   agreed Heisenberg 03/05/10 10:37:10 PM
#29   only 23 mil OS is that current going TecNasty 03/05/10 10:08:50 PM
#28   Looking at the chart it looks promising! TecNasty 03/05/10 10:08:14 PM
#27   For a board that is 3 years old TecNasty 03/05/10 10:07:50 PM
#26   Thats some nice news should get fun. TecNasty 03/05/10 10:04:32 PM
#24   159 million barrels of oil and 1.8 trillion gatorlives 01/25/10 09:07:37 AM
#22   Estimated to be in excess of $38 Million gatorlives 01/19/10 04:36:56 PM
#21   1st Drill now within 40 days? gatorlives 01/14/10 08:18:41 PM
#20   The N. McFaddin Field has 87 productive zones!! gatorlives 01/11/10 09:35:19 AM
#18   Great news on the status of the Koliba gatorlives 01/04/10 09:21:01 AM
#17   after Exxon's purchase of XTO I'm a believer gatorlives 12/30/09 12:24:30 PM
#16   DBTC 1-50 R/S J U ICE 05/02/08 01:13:47 PM
#15   Here is the chart.. Drugdoctor 12/10/07 11:18:32 AM
#14   DBTC reported NET PROFITS - now that is Drugdoctor 12/09/07 09:31:00 PM
#13   Nice revenues, restricted shares used for payment to Drugdoctor 12/07/07 06:25:44 PM
#12   Nice call on this one... Revenues - low Drugdoctor 12/07/07 12:18:30 PM
#11   anyone here?? this is the bets stock i texturedstefan 12/05/07 12:27:14 AM
#10   Diabetes drug linked to heart attacks, death gogo569 05/22/07 03:58:12 AM
#9   over 200% in a day(212.5) HOD (.06) Greencake 05/22/07 01:29:59 AM
#8   i never lost a penny on this pos. eagle_2975 12/12/05 11:48:10 PM
#7   saw that. that big RS today. PDC ™ 12/12/05 11:29:41 PM
#6   The company just recently started into a new Mr. Bill 12/12/05 11:18:45 PM
#5   looks really good bill .... prolly join ya PDC ™ 12/12/05 09:58:11 PM
#4   rotf. hehe. we know whats up. PDC ™ 12/12/05 09:57:18 PM
#3   Thanks for your suggestion. Same was said DNRE, Mr. Bill 12/12/05 07:13:36 PM
#2   This company has virtually no assets and no eagle_2975 12/11/05 02:31:29 PM
#1   DBTC- .055(4) x .06(1) SCHB boxing. Possible Merger Mr. Bill 12/10/05 04:40:00 PM